0001209191-21-008750.txt : 20210209
0001209191-21-008750.hdr.sgml : 20210209
20210209152944
ACCESSION NUMBER: 0001209191-21-008750
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210209
FILED AS OF DATE: 20210209
DATE AS OF CHANGE: 20210209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HEALY JAMES
CENTRAL INDEX KEY: 0001245624
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39988
FILM NUMBER: 21605998
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bolt Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001641281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472804636
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-665-9295
MAIL ADDRESS:
STREET 1: 900 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Bolt Therapeutics, Inc.
DATE OF NAME CHANGE: 20150504
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-09
0
0001641281
Bolt Biotherapeutics, Inc.
BOLT
0001245624
HEALY JAMES
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
1
0
0
0
Common Stock
2021-02-09
4
C
0
1104209
A
1104209
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2021-02-09
4
C
0
1200228
A
2304437
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2021-02-09
4
P
0
450000
20.00
A
2754437
I
By Sofinnova Venture Partners X, L.P.
Series C-1 Preferred Stock
2021-02-09
4
C
0
1104209
0.00
D
Common Stock
1104209
0
I
By Sofinnova Venture Partners X, L.P.
Series C-2 Preferred Stock
2021-02-09
4
C
0
1200228
0.00
D
Common Stock
1200228
0
I
By Sofinnova Venture Partners X, L.P.
The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
The securities reported herein are held of record by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is one of three managing members of SM X and may be deemed to have shared voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.
/s/ Brian Woodard, Attorney-in-Fact
2021-02-09